Valuation: InspireMD

Market Cap 32.05M 28.19M 26.66M 24.18M 45.41M 3.08B 45.67M 319M 123M 1.57B 120M 118M 5.05B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 32.05M 28.19M 26.66M 24.18M 45.41M 3.08B 45.67M 319M 123M 1.57B 120M 118M 5.05B EV / Sales 2026 *
3.27x
EV / Sales 2027 * 1.59x
Free-Float
80.03%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 2019-12-31
Director of Finance/CFO 58 2025-06-24
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 71 2017-06-01
Director/Board Member 68 2013-02-06
Director/Board Member 62 2019-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-3.81%+32.01% - - 32.05M
+1.08%+0.41%-25.39%+0.69% 106B
+0.05%-1.70%-23.49%-0.98% 11.29B
+2.67%-1.84%+98.40%+108.08% 9.35B
-0.68%-2.36%-49.71%-67.13% 4.11B
-0.10%+4.24%-22.13%+26.96% 2.49B
-0.71%-7.55%-9.37%-65.07% 2.02B
-2.05%-2.61% - - 1.9B
-0.80%-2.03%-22.63%-32.22% 1.52B
Average -0.65%-1.73%-7.76%-4.24% 17.29B
Weighted average by Cap. -0.18%-0.14%-17.16%+5.01%

Financials

2026 *2027 *
Net sales 9.8M 8.62M 8.15M 7.39M 13.88M 941M 13.96M 97.58M 37.69M 480M 36.79M 35.99M 1.54B 20.13M 17.71M 16.74M 15.19M 28.52M 1.93B 28.69M 200M 77.42M 986M 75.58M 73.95M 3.17B
Net income - -
Net Debt - -
Logo InspireMD
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Employees
-